by Peter Dizikes, Massachusetts Institute of Technology

Robin Scheffler and his new book, “A Contagious Cause: The American Hunt for Cancer Viruses and the Rise of Molecular Medicine.” Credit: Jon Sachs/SHASS Communications

In 1961, people in the suburb of Niles, Illinois, experienced what they termed a "cancer epidemic." Over a dozen children in the town were diagnosed with leukemia within a short time. Fears quickly spread that the illness could be contagious, carried by some type of "cancer virus." News coverage soon identified several other towns with apparent "cancer clusters," as well. Belief that cancer was a simple contagion, like polio or the flu, kept bubbling up.

"People wrote [to medical authorities] well into the 1960s asking, 'I lived in a house where somebody had cancer. Am I going to catch cancer?'" says Robin Scheffler, the Leo Marx CD Assistant Professor in the History and Culture of Science and Technology at MIT.

Those fears were taken seriously. The National Cancer Institute (NCI) created the Special Virus Leukemia Program in 1964 and over the next 15 years spent more than $6.5 billion (in 2017 dollars) on cancer virus research intended to develop a vaccine. That's more than the funding for the subsequent Human Genome Project, as Scheffler points out.

The results of that funding were complex, unanticipated—and significant, as Scheffler details in his new book, A Contagious Cause: The American Hunt for Cancer Viruses and the Rise of Molecular Medicine, published this week by the University of Chicago Press.

In the process, scientists did not find—and never have—a single viral cause of cancer. On the other hand, as a direct result of the NCI's funding project, scientists did find oncogenes, the type of gene which, when activated, can cause many forms of cancer.

"That investment helped drive the field of modern molecular biology," Scheffler says. "It didn't find the human cancer virus. But instead of closing down, it invented a new idea of how cancer is caused, which is the oncogene theory."

As research has continued, scientists today have identified hundreds of types of cancer, and about one out of every six cases has viral origins. While there is not one "cancer virus," some vaccinations reduce susceptibility to certain kinds of cancer. In short, our understanding of cancer has become more sophisticated, specific, and effective—but the path of progress has had many twists and turns.

Less insurance, more research
As Scheffler details in his book, fears that cancer was a simple contagion can be traced back at least to the 18th century. They appear to have gained significant ground in the early 20th-century U.S., however, influencing medical research and even hospital design.

The rise of massive funding for cancer research is mostly a post-World War II phenomenon; like much of Scheffler's narrative, its story contains developments that would have been very hard to predict.

For instance, as Scheffler chronicles, one of the key figures in the growth of cancer research was the midcentury health care activist Mary Lasker, who with her husband had founded the Lasker Foundation in 1942, and over time helped transform the American Cancer Society.

During the presidency of Harry S. Truman, however, Lasker's main goal was the creation of universal health insurance for Americans—an idea that seemed realistic for a time but was eventually shot down in Washington. That was a major setback for Lasker. In response, though, she became a powerful advocate for federal funding of medical research—especially through the National Institutes of Health (NIH), and the NCI, one of the NIH's arms.

Scheffler calls this tradeoff—less government health insurance, but more biomedical research—the "biomedical settlement," and notes that it was unique to the U.S. at the time. By contrast, in grappling with cancer through the 1960s, Britain and France, for example, put more relative emphasis on treatment, and Germany looked more extensively at environmental issues. Since the 1970s, there has been more convergence in the approaches of many countries.

"The term 'biomedical settlement' is a phrase I created to describe an idea that seems commonplace in the United States but is actually very extraordinary in the context of other industrial nations—which is, we will not federalize health care, but we will federalize health research," Scheffler says. "It's remarkable to keep the government out of one but invite it into the other."

And while observers of the U.S. scientific establishment today know the NIH as a singular research force, they probably don't think of it as compensation, in a sense, for the failed policy aims of Lasker and her allies.

"Someone like Mary Lasker is one of the architects of the settlement out of her conviction there were ways to involve the federal government even if they couldn't provide medical care," Scheffler adds.

Fighting through frustration

The core of A Contagious Cause chronicles critical research developments in the 1960s and 1970s, as biologists made headway in understanding many forms of cancer. But beyond its rich narrative about the search for a single cancer virus, A Contagious Cause also contains plenty of material that underscores the highly contingent, unpredictable nature of scientific discovery.

From stymied scientists to angry activists, many key figures in the book seemed to have reached dead ends before making the advances we now recognize. Yes, science needs funding, new instrumentation, and rich theories to advance. But it can also be fueled by frustration.

"The thing I find interesting is that there are a lot of moments of frustration," Scheffler says. "Things don't go the way people want, and they have to decide what they're going to do next. I think often the history of science focuses on moments of discovery, or highlights great innovations and their successes. But talking about frustration and failure is also a very important topic to highlight in terms of how we understand the history of science."

A Contagious Cause has received praise from other scholars. Angela Creager, a historian of science at Princeton University, has called it "powerfully argued" and "vital reading for historians of science and political historians alike."

For his part, Scheffler says he hopes his book will both illuminate the history of cancer research in the U.S. and underscore the need for policymakers to apply a broad set of tools as they guide our ongoing efforts to combat cancer.

"Cancer is a molecular disease, but it's also an environmental disease and a social disease. We need to understand the problem at all those levels to come up with a policy that best confronts it," Scheffler says.

Provided by Massachusetts Institute of Technology 

This story is republished courtesy of MIT News (web.mit.edu/newsoffice/), a popular site that covers news about MIT research, innovation and teaching.